Tobias Cantz
Prof. of Translational Hepatology and Stem Cell Biology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Background: Hereditary intrahepatic cholestasis is caused by variants of various genes involved in enterohepatic bile circulation, metabolization, and conjugation. Originally classified into 3 groups, the number of contributing genes is still increasing, underlining the need for a deeper understanding of the molecular interaction during intrahepatic cholestasis. Methods: In the present study, we investigate the interplay of heterozygous variants in 3 cholestasis-associated genes ( ABCB11 , ABCB4 , and MYO5B ) by exploiting iPSC-based hepatic organoids from a patient suffering from recurrent intrahepatic cholestasis. Results: Functional characterization of MRP2-mediated cholyl-lysyl-fluorescein (CLF) and BSEP-mediated Tauro-nor-THCA-24-DBD transport demonstrated a marked reduction of transport in MYO5B-deficient organoids, in comparison to unaffected control organoids. Moreover, iPSC-based organoids derived from the patient carrying 3 heterozygous variants in ABCB11 , ABCB4 , and MYO5B also exhibited absence of BSEP-mediated Tauro-nor-THCA-24-DBD transport, but functional MRP2-mediated CLF-transport. Interestingly, CRISPR/Cas9-mediated correction of the mutated ABCB11 allele could not restore the impaired BSEP function, suggesting the heterozygous MYO5B variant as the main driver of the transport deficiency. In fact, CRISPR/Cas-mediated correction of the MYO5B variant finally resulted in a restoration of the BSEP-mediated Tauro-nor-THCA-24-DBD transport. Conclusions: iPSC-based organoids serve as an authentic model for functional assessment of the hepatobiliary transport with fluorescent substrates. This allows the characterization of variants of uncertain significance and other variants in cholestasis-associated genes and revealed that a heterozygous MYO5B variant increases the susceptibility to defective hepatobiliary BSEP-mediated transport.
Year:
2025
The advent of innovative techniques, such as the CRISPR/Cas system, has opened up a new range of possibilities for modifying the genome, with the potential to address previously unmet therapeutic needs of patients with genetic diseases. These new possibilities have not only raised ethical concerns but also challenged existing classifications of genome modification techniques. While the legal status of some of these new therapies remains uncertain, there is an ongoing debate within philosophy of biology about the information-related metaphors adopted by scientists to describe and classify the genome and its therapeutic modification. Given the continuing advance of new genomic therapies, we show, employing an interdisciplinary approach, that a comprehensive framework for the classification of these technologies is needed to resolve legal and philosophical issues. The first section provides an analysis of the current state of novel genome-modifying techniques in medical genetics. In the second section, we assess the regulatory status of these techniques within the European regulatory framework for advanced therapy medicinal products (ATMPs). Drawing on these results, we argue in the third section from a philosophical perspective that metaphors, such as ‘editing’ the genome, which are based on a conception of the genome as linear information, cannot adequately capture the breadth of advanced genomic technologies. To accurately categorise these techniques in a manner that meets their diverse applications, we propose introducing the umbrella term ‘somatic genomic therapies’ (SGTs). Urging an integrative approach to defining and classifying new technologies in medical genetics, we advocate for the development of an integrative concept of SGTs.
Year:
2025
Year:
2025
Cas9–SpRY is an engineered variant of the Streptococcus pyogenes Cas9 with relaxed PAM recognition, which can technically be utilized at any target in the genome but some targets are addressed with low efficiency. Here, we show that a previously unexplored motif at the turn and beginning of α-helix 51 (TH51) can be engineered to improve both nuclease and prime-editing activity of Cas9–SpRY. Interaction of the lysine-rich PID loop 2 (PL2) with the target DNA downstream of the PAM (post-PAM) mediates initiation of R-loop formation and subsequent cleavage yet it was unclear if other regions of the PID engage with post-PAM as well. To this end, the NAAN–PAM-targeting iSpyMac hybrid nuclease, which lacks all lysine residues in PL2, was compared with Cas9–SpRY at identical targets using molecular dynamics simulation and in cell culture models, uncovering four crucial post-PAM-interacting lysines in TH51 and TH53 of iSpyMac. Ectopic insertion of a lysine-rich PL2 into iSpyMac boosted its nuclease and prime-editing activities and, in turn, Cas9–SpRY benefited from certain lysine-rich TH51 motifs. Specifically, TH51 from an uncultured Abiotrophia Cas9 species boosted overall Cas9–SpRY activity. Together, this study demonstrates that engineering of post-PAM interacting motifs opens new avenues for the design of advanced CRISPR enzymes.
Year:
2025
Year:
2025
Der Begriff „Gentherapie“ ist nicht mehr passgenau verwendbar, wenn beispielsweise neben der additiven Ergänzung defekter Gene auch gezielte DNA - und Genexpression-Änderungen mittels RNA und CRISPR /Cas-basierter Verfahren adressiert werden. Solche neuen somatischen genomischen Therapien stellen aber die Medizin vor neue Herausforderungen. Insbesondere die Individualisierung solcher Therapien bricht mit herkömmlichen Paradigmen der Arzneimittelentwicklung und bedingt neue Konzepte für eine kosteneffiziente Herstellung und angepasste Regulierung.
Year:
2025
The lysosomal storage disorder Fabry disease results from α-galactosidase A deficiency, leading to excessive glycosphingolipid substrate accumulation, primarily globotriaosylceramide (Gb3). While the underlying molecular mechanisms remain elusive, multi-systemic complications ultimately culminate in premature death, with heart failure being the leading cause of death. Current treatment options fail to treat Fabry disease adequately and only delay its progression. Preclinical studies on an alternative approach, systemic delivery of nucleoside-modified GLA mRNA (modGLA), suggest improved effectiveness over existing therapies in reducing glycosphingolipid levels in the heart. It remains unclear whether modGLA can rescue Fabry cardiomyopathy phenotypes at the cellular level, which are not faithfully recapitulated in current animal models. To address this, we investigated characteristic phenotypes in two new models of Fabry cardiomyopathy utilizing human iPSC-derived cardiomyocytes in transcriptomic and functional analyses. These human Fabry disease cardiomyocytes displayed broad transcriptional dysregulation, apoptosis, mitochondrial dysfunction, impaired reactive oxygen species handling, as well as enhanced decay parameters of calcium transients. Mechanistically, we identified hyperphosphorylated phospholamban as a major player in this calcium dysregulation. Strikingly, modGLA therapy of Fabry cardiomyocytes restored α-galactosidase A enzyme activity, reduced glycosphingolipid deposition, and normalized the observed molecular alterations, supporting modGLA therapy as a promising strategy for the treatment of Fabry disease.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (14)
Ernest Fraenkel
Massachusetts Institute of Technology
Asha Balakrishnan
Researcher/ Group leader
Hannover Medical School
Tomo Šarić
Group leader
-
Tom Luedde
-
Kurt Paul Pfannkuche
Principal Investigator
University of Cologne
Hans-Georg Dederer
Full Professor
University of Passau
Mariane Fraguas-Eggenschwiler
Postdoctoral Researcher at Prof. Dr. Heiner Niemann's group
Medizinische Hochschule Hannover
Jeannine Hoepfner
Chemiker / Biochemiker
Hannover Medical School
Christian Bär
Professor / Group Leader Regenerative Cardiology
-
Bernd Fleischmann
Professor
Rheinische Friedrich-Wilhelms-Universität Bonn
Falk Buettner
Professor
Medizinische Hochschule Hannover
Giacomo Volpe
Associate Professor of Applied Biology
University of Bari Aldo Moro
Thomas Thum
Director
Hannover Medical School
Jörn Stitz
Professor
TH Köln - University of Applied Sciences
Make your next move.
Prepare your application
Review drafts before you send them.